Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Zhang W, Choi Y, Haynes LM, Harcourt JL, Anderson LJ, Jones LP, Tripp RA.

J Virol. 2010 Jan;84(2):1148-57. doi: 10.1128/JVI.01755-09. Epub 2009 Oct 28.

2.

Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.

Choi Y, Mason CS, Jones LP, Crabtree J, Jorquera PA, Tripp RA.

Viral Immunol. 2012 Jun;25(3):193-203. doi: 10.1089/vim.2011.0094. Epub 2012 May 2.

3.

Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.

Boyoglu-Barnum S, Todd SO, Meng J, Barnum TR, Chirkova T, Haynes LM, Jadhao SJ, Tripp RA, Oomens AG, Moore ML, Anderson LJ.

J Virol. 2017 Apr 28;91(10). pii: e02059-16. doi: 10.1128/JVI.02059-16. Print 2017 May 15.

PMID:
28275196
4.
5.

Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses.

Chirkova T, Boyoglu-Barnum S, Gaston KA, Malik FM, Trau SP, Oomens AG, Anderson LJ.

J Virol. 2013 Dec;87(24):13466-79. doi: 10.1128/JVI.01741-13. Epub 2013 Oct 2.

6.

Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.

Jorquera PA, Choi Y, Oakley KE, Powell TJ, Boyd JG, Palath N, Haynes LM, Anderson LJ, Tripp RA.

PLoS One. 2013 Sep 10;8(9):e74905. doi: 10.1371/journal.pone.0074905. eCollection 2013.

7.

Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Murawski MR, McGinnes LW, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Heaton PM, Fraire AE, Morrison TG.

J Virol. 2010 Jan;84(2):1110-23. doi: 10.1128/JVI.01709-09. Epub 2009 Nov 4.

8.

Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice.

Rey GU, Miao C, Caidi H, Trivedi SU, Harcourt JL, Tripp RA, Anderson LJ, Haynes LM.

PLoS One. 2013 Dec 23;8(12):e83075. doi: 10.1371/journal.pone.0083075. eCollection 2013.

10.

A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.

Wiegand MA, Gori-Savellini G, Gandolfo C, Papa G, Kaufmann C, Felder E, Ginori A, Disanto MG, Spina D, Cusi MG.

J Virol. 2017 Apr 28;91(10). pii: e02298-16. doi: 10.1128/JVI.02298-16. Print 2017 May 15.

PMID:
28250126
11.

Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.

Mok H, Lee S, Utley TJ, Shepherd BE, Polosukhin VV, Collier ML, Davis NL, Johnston RE, Crowe JE Jr.

J Virol. 2007 Dec;81(24):13710-22. Epub 2007 Oct 10.

12.

Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.

Lee S, Quan FS, Kwon Y, Sakamoto K, Kang SM, Compans RW, Moore ML.

Antiviral Res. 2014 Nov;111:129-35. doi: 10.1016/j.antiviral.2014.09.005. Epub 2014 Sep 18.

13.

CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.

Chirkova T, Lin S, Oomens AG, Gaston KA, Boyoglu-Barnum S, Meng J, Stobart CC, Cotton CU, Hartert TV, Moore ML, Ziady AG, Anderson LJ.

J Gen Virol. 2015 Sep;96(9):2543-56. doi: 10.1099/vir.0.000218. Epub 2015 Jun 25.

14.

Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins.

McGinnes LW, Gravel KA, Finberg RW, Kurt-Jones EA, Massare MJ, Smith G, Schmidt MR, Morrison TG.

J Virol. 2011 Jan;85(1):366-77. doi: 10.1128/JVI.01861-10. Epub 2010 Oct 27.

15.

Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.

Kim KH, Lee YT, Hwang HS, Kwon YM, Kim MC, Ko EJ, Lee JS, Lee Y, Kang SM.

J Virol. 2015 Nov;89(22):11692-705. doi: 10.1128/JVI.02018-15. Epub 2015 Sep 9.

16.
17.

Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.

Elliott MB, Pryharski KS, Yu Q, Boutilier LA, Campeol N, Melville K, Laughlin TS, Gupta CK, Lerch RA, Randolph VB, LaPierre NA, Dack KM, Hancock GE.

J Virol. 2004 Aug;78(16):8446-54.

18.
19.

Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.

Garlapati S, Garg R, Brownlie R, Latimer L, Simko E, Hancock RE, Babiuk LA, Gerdts V, Potter A, van Drunen Littel-van den Hurk S.

Vaccine. 2012 Jul 27;30(35):5206-14. doi: 10.1016/j.vaccine.2012.06.011. Epub 2012 Jun 17.

PMID:
22713718
20.

A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.

Rigter A, Widjaja I, Versantvoort H, Coenjaerts FE, van Roosmalen M, Leenhouts K, Rottier PJ, Haijema BJ, de Haan CA.

PLoS One. 2013 Aug 12;8(8):e71072. doi: 10.1371/journal.pone.0071072. eCollection 2013.

Supplemental Content

Support Center